Pazopanib - dilemmas in kidney cancer treatment
Journal Title: OncoReview - Year 2013, Vol 3, Issue 4
Abstract
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in initial therapy where there are few drugs with similar properties. The choice of drug in first line is based on prognostic factors and clinical profiles of drug and patient. Important are also patient’s expectations connected with treatment. COMPARZ trail shows results of comparison between sunitinib and pazopanib which both are given in first line treatment of mRCC. Based on this the decision of choosing proper drug seems to be easier.
Authors and Affiliations
Piotr Tomczak
Keywords
Related Articles
- EP ID EP67737
- DOI -
- Views 190
- Downloads 0
Physical activity and cancer
Physical activity has been shown to decrease the incidence of breast and colon cancers and most likely of cancers of the prostate, endometrium and lung. The mechanism of this effect is very complex and not completely und...
Zaburzenia psychiczne u chorych na nowotwory - podejście kliniczne
Pacjent z chorobą nowotworową nie tylko mierzy się z chorobą pierwotną, ale także narażony jest na stany emocjonalne, które przy niesprzyjających warunkach i dużym obciążeniu mogą prowadzić do depresji, zwiększonego lęku...
Cardiooncological balance in a 75-year-old male with a hepatocellular carcinoma CS IV and a congestive heart failure NYHA III „de novo”
The case reports about a 75-years-old man without a previous medical history, in whom a heart failure NYHA III de novo was diagnosed together with persistent atrial fibrillation and hepatocellular carcinoma in clinical s...
Cardiac Biomarkers and Early Detection of Cardiotoxicity
Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study
Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HE -1 and HER-2 tyrosine kinase receptors....